aTyr Pharma, Inc. (FRA:471A)

Market Cap	86.50M -72.8%
Revenue (ttm)	161.94K -19.1%
Net Income	-64.03M
EPS	-0.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	250
Open	0.7750
Previous Close	0.7900
Day's Range	0.7750 - 0.7750
52-Week Range	0.4680 - 5.7000
Beta	n/a
RSI	64.35
Earnings Date	Mar 17, 2026

About aTyr Pharma

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 61
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 471A

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Financial numbers in USD